U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07609901) titled 'Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers' on May 20.
Brief Summary: The primary objective is to assess the effect of vaccination with neopeptide-loaded dendritic cells on disease-free survival (DFS) compared to placebo in LS subjects who are known to be carrier of a germline MMR-gene mutation with no signs of disease.
Study Start Date: Oct. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Lynch Syndrome
Intervention:
BIOLOGICAL: Arm A: DC vaccination
Subjects in the DC vaccination arm will receive a maximum of 2 cycles each consisting of 3 DC injections intranodally (3-7x10^6 DC)
BIOLOGICAL: Arm B: Plac...